CYP2D6 genotype and outcome in tamoxifen treated early breast cancer.

ABSTRACT:

Background and purpose

The clinical significance of individual CYP2D6 activity for the outcome of tamoxifen treatment in early breast cancer is unclear. Our previous investigation in patients diagnosed over the period 1998-2000 indicated an association between reduced CYP2D6 activity and poor outcome in premenopausal women. The aim of this study was to investigate the association between CYP2D6 genotype and clinical outcome in a larger tamoxifen treated cohort.

Patients/material and methods

Swedish breast cancer patients who initiated adjuvant tamoxifen treatment over the period 2006-2014 constituted the full study cohort. Clinical information was collected from medical records. Data on endocrine treatment, use of CYP2D6 inhibitors was retrieved from the Swedish Prescribed D

SUBMITTER: Thoren L 

PROVIDER: S-EPMC12239131 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature